(Rac)-JBJ-04-125-02

Target: This ligand targets allosteric sites on mutant EGFR kinase domains, including L858R/T790M contexts in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for allosteric sites on mutant EGFR kinase domains, including L858R/T790M contexts. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings allosteric sites on mutant EGFR kinase domains into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Degradation Studies: (Rac)-JBJ-04-125-02 can be used as a ligand component to build PROTACs that recruit an E3 ligase and drive ubiquitination of the target protein. This enables systematic evaluation of degradation potency, including concentration–response behavior, time dependence, and dependence on proteasome activity in cellular models.

• E3 Ligase Recruitment Optimization: The ligand can support PROTAC design strategies that tune E3 ligase engagement by varying linker length, attachment position, and stereochemistry. Researchers can compare degradation efficiency across E3 ligase choices and PROTAC architectures to identify constructs that maximize target engagement while minimizing off-target degradation.

• Stereochemistry-Driven Activity Mapping: Because (Rac)-JBJ-04-125-02 is racemic, it is suitable for investigating how stereochemical composition affects ternary complex formation and degradation outcomes. Experimental workflows may include separating enantiomers or using stereodefined analogs to correlate binding/engagement metrics with observed reductions in target protein levels.

• Mechanistic Proteolysis Profiling: PROTACs incorporating this ligand can be used to dissect degradation mechanisms, such as ubiquitin chain formation and requirement for specific trafficking or cofactors. By combining degradation assays with ubiquitination readouts and rescue experiments (e.g., E3 disruption or proteasome inhibition), researchers can validate causality in targeted proteolysis.

Structure: The structure of (Rac)-JBJ-04-125-02 is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; phenol or alcohol functionality; halogenated aryl/heteroaryl ring system. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.